Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages 916-922

  Valcárcel, David ^a   Ademà, Vera ^b,c   Solé, Francesc ^b   Ortega, Margarita ^a   Nomdedeu, Benet ^d   Sanz, Guillermo ^e   Luño, Elisa ^g   Cañizo, Consuelo ^h   De La Serna, Javier ⁱ   Ardanaz, Maite ^j   Marco, Victor ^k   Collado, Rosa ^f   Grau, Javier ^l   Montoro, Julia ^a   Mallo, Mar ^b   Vallespí, Teresa ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^g Hospital Universitario   (Spain)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j HOSPITAL TXAGORRITXU   (Spain)

^k HOSPITAL ARNAU DE VILANOVA   (Spain)

^l Institut Josep Carreres contra la leucemia   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYCLOSPORIN A; HEMOGLOBIN; LENALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW; CANCER SURVIVAL; CHROMOSOME 5; CHROMOSOME ABERRATION; CYTOGENETICS; DISEASE MARKER; DISEASE REGISTRY; FEMALE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOSOMAL KARYOTYPE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE COUNT;

ABNORMAL KARYOTYPE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KARYOTYPING; MALE; MIDDLE AGED; MONOSOMY; MYELODYSPLASTIC SYNDROMES; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84875758862     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.6073     Document Type: Article

References (17)

1. Tefferi A, Vardiman JW: Myelodysplastic syndromes. N Engl J Med 361:1872-1885, 2009.
2. Haase D, Germing U, Schanz J, et al: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 110: 4385-4395, 2007.
3. Solé F, Luño E, Sanzo C, et al: Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 90: 1168-1178, 2005.
4. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079- 2088, 1997.
5. Breems DA, van Putten WL, de Greef GE, et al: Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26:4791-4797, 2008.
6. Patnaik MM, Hanson CA, Hodnefield JM, et al: Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia 25:266-270, 2011.
7. Belli CB, Bengió R, Aranguren PN, et al: Partial and total monosomal karyotypes in myelodysplastic syndromes: Comparative prognostic relevance among 421 patients. Am J Hematol 86:540-545, 2011.
8. Vaidya R, Caramazza D, Begna KH, et al: Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood 117:5612-5615, 2011.
9. Shaffer LG, Slovak ML, Campbell LJ (eds): ISCN 2009: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 2009.
10. Chun K, Hagemeijer A, Iqbal A, et al: Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study. Leuk Res 34:160-165, 2010.
11. Schanz J, Tüchler H, Solé F, et al: A new, comprehensive cytogenetic scoring system for primary myelodysplastic syndromes and oligoblastic AML following MDS derived from an international database merge. J Clin Oncol 30:820-829, 2012.
12. Solé F, Espinet B, Sanz GF, et al: Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes: Grupo Cooperativo Español de Citogé netica Hematológica. Br J Haematol 108:346-356, 2000.
13. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Statist Assoc 53:457-481, 1958.
14. Cox D: Regression models and life tables. J R Stat Soc 34:187-220, 1972.
15. Itzykson R, Thépot S, Eclache V, et al: Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia 25:1207-1209, 2011.
16. Itzykson R, Thépot S, Quesnel B, et al: Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117:403-411, 2011.
17. Tiu RV, Gondek LP, O'Keefe CL, et al: Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 117: 4552-4560, 2011.